Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy

Autor: Inês Barros, Luís Pereira de Almeida, Catarina Oliveira Miranda, António Alves da Silva
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
ARDS
ALI
acute lung injury
IDO
indoleamine 2
3 dioxygenase
IFN-y
interferon y
Endocrinology
Diabetes and Metabolism
Cell- and Tissue-Based Therapy
Disease
BM-MSC
bone marrow mesenchymal stromal cells
LVEF
left ventricle ejection fraction
medicine.disease_cause
Bioinformatics
Cytokine storm
Cell therapy
0302 clinical medicine
Pleiotropic therapy
Immunology and Allergy
TMPRSS2
transmembrane protease serine 2
Coronavirus
education.field_of_study
ACE2
angiotensin converting enzyme 2
IBD
inflammatory bowel disease
GMCSF
granulocyte-macrophage colony-stimulating factor
FGF7
fibroblast growth factor 7
GI
gastrointestinal
FDA
US food and drug administration
Treg
T regulatory
030220 oncology & carcinogenesis
MSC
mesenchymal stromal cells
LPS
lipopolysaccharide
DCs
dendritic cells
NK
natural killer
IV
intravenous
TNF-a
tumor necrosis factor alpha
Multiple Organ Failure
Population
Immunology
JEV
Japanese encephalitis virus
CNS
central nervous system
Mesenchymal Stem Cell Transplantation
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
Article
CM
conditioned-medium
General Biochemistry
Genetics and Molecular Biology
MERS
middle east respiratory syndrome
03 medical and health sciences
MCP-1
Monocyte Chemoattractant Protein 1
EVs
extracelular vesicules
medicine
CD
Crohn’s disease
Cytokines/chemokines
Humans
SARS
severe acute respiratory syndrome
education
Mesenchymal stromal/stem cells
Th
T helper
BBB
blood-brain-barrier
ARDS
acute respiratory distress syndrome
COVID-19
Coronavirus Disease of 2019
business.industry
SARS-CoV-2
Mesenchymal stem cell
COVID-19
Mesenchymal Stem Cells
medicine.disease
MB-MSC
menstrual blood mesenchymal stromal cells
IL
interleukin
Clinical trial
030104 developmental biology
VEGF
vascular endotelhial growth factor
business
Zdroj: Cytokine & Growth Factor Reviews
ISSN: 1359-6101
DOI: 10.1016/j.cytogfr.2020.12.002
Popis: Highlights • SARS-CoV-2 can infect multiple organs leading to their dysfunction, so a pleiotropic therapy would be advantageous. • MSC: MSC can simultaneously address injuries in multiple organs and promote their repair. • MSC, immunomodulators by excellence, may counteract infection and cytokine storm in COVID-19 patients. • MSC therapy is being tested in clinical trials for COVID-19 patients and proved to be safe and effective so far. • More clinical studies, addressing MSC use for COVID-19, with bigger cohorts and suitable controls are welcome.
The devastating global impact of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has prompted scientists to develop novel strategies to fight Coronavirus Disease of 2019 (COVID-19), including the examination of pre-existing treatments for other viral infections in COVID-19 patients. This review provides a reasoned discussion of the possible use of Mesenchymal Stromal Cells (MSC) or their products as a treatment in SARS-CoV-2-infected patients. The main benefits and concerns of using this cellular therapy, guided by preclinical and clinical data obtained from similar pathologies will be reviewed. MSC represent a highly immunomodulatory cell population and their use may be safe according to clinical studies developed in other pathologies. Notably, four clinical trials and four case reports that have already been performed in COVID-19 patients obtained promising results. The clinical application of MSC in COVID-19 is very preliminary and further investigational studies are required to determine the efficacy of the MSC therapy. Nevertheless, these preliminary studies were important to understand the therapeutic potential of MSC in COVID-19. Based on these encouraging results, the United States Food and Drug Administration (FDA) authorized the compassionate use of MSC, but only in patients with Acute Respiratory Distress Syndrome (ARDS) and a poor prognosis. In fact, patients with severe SARS-CoV-2 can present infection and tissue damage in different organs, such as lung, heart, liver, kidney, gut and brain, affecting their function. MSC may have pleiotropic activities in COVID-19, with the capacity to fight inflammation and repair lesions in several organs.
Databáze: OpenAIRE
Externí odkaz: